Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study

Background There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2021-01, Vol.124 (2), p.407-413
Hauptverfasser: Hajiev, Saur, Allara, Elias, Motedayеn Aval, Leila, Arizumi, Tadaaki, Bettinger, Dominik, Pirisi, Mario, Rimassa, Lorenza, Pressiani, Tiziana, Personeni, Nicola, Giordano, Laura, Kudo, Masatoshi, Thimme, Robert, Park, Joong-Won, Taddei, Tamar H., Kaplan, David E., Ramaswami, Ramya, Pinato, David J., Sharma, Rohini
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly. Methods In an international, multicentre cohort study, outcomes for those aged 7 cm) (39 vs 33%, p  
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-020-01116-9